-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: diagnostics
#BIO2013 Company Snapshot: Acreo Swedish ICT
The BIO Business Forum at the International Convention is in full swing! Partnering meetings began at 8:00am this morning, with the first Exhibitor Partnering meetings starting later in the day after the Opening Ceremony. Presentations have also begun. We’ve been highlighting a few presenters in our snapshot campaign, and below is more information on another: Acreo Swedish ICT, a diagnostics and platform technologies company presenting Wednesday at 10:30am in the Chicago Cubs Room. Read more Read More >
BIO’s Prometheus v. Mayo Amicus Brief Filed
BIO filed an amicus brief in the Prometheus v. Mayo Clinic case. In this case the Supreme Court is being asked to decide whether diagnostic and personalized medicine claims that depend on a correlation of observed phenomena should be excluded from the patent system at the outset, as patent-ineligible abstract ideas or “laws of nature.” BIO’s brief argues that these judicially-created exclusions from patent-eligibility have traditionally been used only under narrow circumstances, and that their Read More >
Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice
Insights in to the molecular and genetic basis of disease are driving new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions. Focusing on these new markets, a panel of industry executives and investors at the 2011 BIO Investor Forum discussed some of the most compelling Read More >
BIO’s New Personalized Medicine and Diagnostics Working Group
The Biotechnology Industry Organization (BIO) represents a diverse portfolio of companies throughout the continuum of personalized medicine. These companies include those that develop therapeutic and diagnostic products, as well as research tools companies that drive innovation in this area. With broad member representation from across the drug, biologic, diagnostic and research tool industries, BIO is uniquely positioned to serve as industry’s key voice on personalized medicine issues. As part of an effort to better utilize Read More >
BIO submits comments on Australian Senate Patent Amendment
The Australian Senate has proposed the Patent Amendment (Human Genes and Biological Materials) Bill 2010 that aims to ban ’gene patents’. From the BIO Submission to Australian Senate Legal Committee on Patent Amendment: This amendment would exclude from patent protection “any” biological material, whether a human gene or otherwise, that is substantially identical to a naturally-occuring biological material. Specifically, the amendment states that the following materials would be catergorically declared unpatentable: “biological materials including their components Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: animal healthcare products, antibiotics, Australia, Australian Senate, Australian Senate Legal Committee on Patent Amendment, biological materials, biotechnology, celss, diagnostics, DNA, DNA patents, drugs, environmental mitigation and remediation, Gene Patents, gene patents, Green Technology, human health, insulin, patent, Patent Amendment (Human Genes and Biological Materials) Bill 2010, proteins, renewable energy, RNA, therapeutics
Tags: animal healthcare products, antibiotics, Australia, Australian Senate, Australian Senate Legal Committee on Patent Amendment, biological materials, biotechnology, celss, diagnostics, DNA, DNA patents, drugs, environmental mitigation and remediation, Gene Patents, gene patents, Green Technology, human health, insulin, patent, Patent Amendment (Human Genes and Biological Materials) Bill 2010, proteins, renewable energy, RNA, therapeutics
